Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Newly Diagnosed Extra-nodal NK/T-cell Lymphoma
NCT04484506Phase 2Recruiting
- Sponsor
- Peking University
- Start
- Oct 2011
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies, Therapeutic Enzymes, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of pegaspargase, cyclophosphamide, vincristine sulfate liposome injection, etoposide, prednisone in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Peking University. Started Oct 2011; status: recruiting.
02
Drugs
pegaspargasecyclophosphamidevincristine sulfate liposome injectionetoposideprednisone
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT04484506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04484506.